VerifiedEvidence: highv1.0.0

Alpha Spending

A group sequential trial method allocating the overall acceptable risk of a false positive across multiple planned interim analyses.

Last reviewedDarrin Baines IP Ltd

Concept Architecture

Concept


Theoretically, Alpha Spending is a statistical methodology used in group sequential and adaptive clinical trial designs to control the overall Type I error rate when multiple interim analyses are performed. It represents the planned allocation of the total allowable significance level across successive analyses while preserving the experiment-wise probability of falsely rejecting the null hypothesis. The concept is founded on sequential hypothesis testing and exists to permit early stopping without inflating the probability of false-positive conclusions.

Mathematically, Alpha Spending is defined through an alpha-spending function that specifies how the cumulative Type I error probability is distributed as information accumulates during a trial. Different spending functions allocate the significance level at different rates, resulting in conservative or aggressive stopping boundaries. Common alpha-spending approaches include the O'Brien?Fleming and Pocock spending functions.

In practice, Alpha Spending is implemented during the design of randomised clinical trials with planned interim analyses. It is estimated according to the information fraction reached at each analysis and is widely applied in confirmatory clinical trials, health technology assessment and health economic evidence generation where early stopping rules must preserve statistical validity.


Purpose


Used to control the overall Type I error rate during interim analyses, define stopping boundaries for sequential trials, preserve statistical validity and support regulatory and health economic decision-making.


Mathematical Formulae

Primary Formula

�(t) = cumulative Type I error spent at information fraction t

where:

  • �(t) = cumulative alpha spent
  • t = information fraction, 0 � t � 1

Supporting Formulae

Information Fraction:

t = I? / I???

O'Brien?Fleming Spending Function:

�(t) = 2 ? 2�(z�/2 / �t)

Pocock Spending Function:

�(t) = � ? ln[1 + (e ? 1)t]

where:

  • I? = information available at interim analysis
  • I??? = planned total information
  • �() = cumulative standard normal distribution
  • z�/2 = standard normal critical value
  • � = overall Type I error

Related Mathematical Methods

  • Group Sequential Design
  • Interim Analysis
  • Sequential Testing
  • Type I Error
  • O'Brien?Fleming Boundary
  • Pocock Boundary
  • Lan?DeMets Alpha Spending Function
  • Information Fraction

Example


A confirmatory clinical trial is designed with an overall two-sided significance level of 0.05 and three planned interim analyses.

After the second interim analysis, the accumulated information fraction is 0.60.

Using a Lan?DeMets implementation of the O'Brien?Fleming alpha-spending function, the cumulative alpha spent at this stage is calculated to determine the corresponding statistical stopping boundary while ensuring that the total Type I error remains 0.05 across all analyses.


Excel Implementation

FunctionExample FormulaHealth Economics Application
LN=0.05*LN(1+(EXP(1)-1)*B2)Calculates Pocock cumulative alpha spending from the information fraction.
SQRT=SQRT(B2)Calculates the square root of the information fraction for O'Brien?Fleming calculations.
NORM.S.INV=NORM.S.INV(1-C2/2)Calculates sequential critical values for interim analyses.
IF=IF(D2<E2,"Stop trial","Continue trial")Applies predefined stopping boundaries during interim monitoring.

VBA (Optional)


A VBA macro can automatically calculate cumulative alpha spending, sequential stopping boundaries and interim monitoring reports throughout a clinical trial.


Sources

  • Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70(3):659?663.
  • O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549?556.
  • Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials.
  • Chow SC, Chang M. Adaptive Design Methods in Clinical Trials. 2nd ed.
  • ICH E9. Statistical Principles for Clinical Trials.

Library

Publications

1
  • Book

    Bayesian Methods in Health Economics — Gianluca Baio, 1st Edition ed., 2012 (Chapman & Hall / CRC Press)

    An overview of Bayesian statistical methods for the analysis of health economic data, covering economic evaluation concepts, statistical cost-effectiveness analysis, Bayesian computation and MCMC, and applied health economic evaluation.

Frequently Asked Questions (6)

  • What is alpha spending?

    A group sequential trial method allocating the overall acceptable risk of a false positive across multiple planned interim analyses.

    Source: Lan & DeMets 1983

  • What problem does alpha spending solve in a trial with interim looks?

    Alpha spending solves the problem that looking at a trial's data repeatedly, at several interim analyses, inflates the chance of a false positive, because each look is another opportunity to cross a significance threshold by chance. It divides the total acceptable risk of a false positive across the planned looks, spending a small portion at each so that the overall risk stays at the intended level. This lets a trial stop early for benefit or harm without abandoning statistical rigour. Rationing the false-positive risk across looks is its purpose. Friedman and colleagues (2015) describe this method.

    Source: Friedman et al. 2015

  • Why is alpha spending needed?

    Alpha spending is needed because examining trial data at multiple interim analyses and testing for significance each time inflates the overall chance of a false positive, so without control the type I error would exceed the intended level. Alpha spending apportions the allowable error across the looks to keep the total at the intended level. So alpha spending is needed to allow interim analyses, which are valuable for stopping trials early for benefit, harm, or futility, without inflating the false positive rate, since repeatedly testing accumulating data would otherwise make a spurious significant result more likely than the nominal alpha suggests.

    Source: Lan & DeMets 1983

  • How does alpha spending work?

    Alpha spending works by defining a spending function that specifies how much of the total alpha is used, or spent, by each interim analysis as a function of the proportion of information accrued, with the cumulative amount reaching the full alpha only at the final analysis. The boundaries for significance at each look are derived from this function. So alpha spending works by allocating portions of the overall error rate across interim analyses according to a chosen spending function, which sets how conservative the early looks are, allowing flexible interim monitoring while ensuring the total type I error does not exceed the intended level over the whole trial.

    Source: Lan & DeMets 1983

  • What are the advantages of alpha spending?

    The advantages of alpha spending include flexibility in the number and timing of interim analyses, since the spending function does not require these to be fixed exactly in advance, only the information fractions; control of the overall type I error across the looks; and the ability to stop a trial early for convincing benefit, harm, or futility while preserving statistical validity. So alpha spending is advantageous for interim monitoring of trials, allowing accumulating data to be examined repeatedly and trials to be stopped early when justified, without inflating the false positive rate, which makes it a widely used approach for the group sequential design and monitoring of clinical trials.

    Source: Lan & DeMets 1983

  • How does alpha spending relate to interim analysis?

    Alpha spending relates to interim analysis as the method that makes repeated interim testing statistically valid: interim analyses examine accumulating trial data before the planned end, and alpha spending controls the error rate across these examinations by allocating the alpha among them. Without such control, interim analyses would inflate the false positive rate. So alpha spending underpins the interim analysis of trials by distributing the overall false positive risk across the interim looks, enabling data monitoring committees to review results periodically and stop trials early when warranted, while ensuring the total type I error remains at the intended level.

    Source: Lan & DeMets 1983

Trust Record

Verified by Dr Darrin Baines

British health economist

Professional identity: darrinbaines.org

Verification date: 10 Dec 2025

Content version: 1.0.0

Canonical Identity

Term code
HE-ES-SA-004

Stable URI · Machine-readable · Resolvable · CC BY 4.0